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Background: CccDNA serves as a template for the production
of HBV pregenomic-RNA and shows viral replication activity. It is
responsible from the persistence of HBV during antiviral therapy.
We report total-DNA and cccDNA levels in the liver biopsy samples
of 6 chronic hepatitis B(CHB) patients during different phases of
undergoing antiviral therapy by a sensitive and speciﬁc quantita-
tive real-time polymerase chain reaction(PCR) assay.
Methods & Materials: All the patients had undetectable serum
HBV-DNA at the time of biopsy. Each patient underwent a liver
biopsy, and a small piece of the biopsy specimens at least 2mm
in length was sent to labaratory in 0.9% NaCl solution. DNA was
extracted from tissue using Alkaline phenol-chloroform- izoamyl
alcohol process. PCR ampliﬁcation was performed by TaqMan real-
time PCR method. Primers and probes for intrahepatic total-DNA,
cccDNA and lamivudine-resistancewere designed using Oligoware
1.0 software program. ABI PRISM 7700 Sequence Detection System
was used for all the analysis.
Results: First patient was recieving lamivudine(LAM) for 5
years. Second and third patient recieving LAM for 38 and 42
months had elevated transaminase for the last 14 and 18 months
despite undetectable serum HBV-DNA. Fourth patient was reciev-
ing LAM add-on adefovir dipivoxil for 63 months following 5
years of LAM. Fifth patient was recieving LAM add-on teno-
fovire disoproxil fumarat(TDV) for 3 months following 9 years
of LAM. Sixth patient was recieving TDV for 3 months follow-
ing one year of pegylated-IFN. Intrahepatic total\cccDNA levels in
patients were 5,6x106\6,4x104, 8,8x107\4x104, 4,9x106\9,5x104,
5,5x106\2,7x104, 5,1x103\-, 9,2x107\1,1x104 coppies\mg.tissue,
respectively. Although all the patients except ﬁrst and second had
normal levels of serum transaminase aswell as undetectable serum
HBV-DNA at the time of biopsy, YMDD mutations were identiﬁed
in all except fourth and sixth one, then treatment regimens were
reconstructed.
Conclusion: Our results show that cccDNA persists in hepato-
cyte nucleus, even in with serological evidence of viral clearance
under the long-term antiviral theraphy and its detection pro-
vides valuable information for the emergence of drug-resistance
to manage treatment early. Investigating the intrahepatic forms of
HBV-DNA is a good implementation for evidence-based medicine
as an alternative in clinical practice. Therefore it is important to
develop standardized assays to be used on clinical samples.
http://dx.doi.org/10.1016/j.ijid.2014.03.1164
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Background: Chronic hepatitis, liver cirrhosis and hepatocellu-
lar carcinoma by HBV and/or HCV are among the leading causes of
death, especially in HIV endemic regions. Though distinct viruses,
HBV, HCV and HIV share common routes of transmission, albeit
at different efﬁciency. Chemotherapy and radiotherapy for cancer
have been associated with reactivation of viral hepatitis, leading to
accelerated hepatitis disease and termination of cancer therapy.
Methods&Materials: The studypopulation comprised 34black
(3 males and 31 females) HIV positive cancer patients due to
undergo chemotherapy or radiotherapy at Dr GeorgeMukhari Aca-
demic hospital, north-west of Pretoria. Routine blood tests, HIV
viral load, CD4+ cell counts and liver function tests (ALT and AST)
were conducted. HBV serological makers were tested with Elecsys
assays (Roche). TheMonolisaHCVantigen-antibodyassaywasused
to screen for HCV. In-house PCR assays were performed to detect
HCV and HBV active infection.
Results: Of the 34 patients, 75% (25) were exposed to HBV and
64% (22)wereHBVDNApositive; 47% (16)hadexposure toHCVand
38% (13)wereHCVRNApositive; and29% (10)were simultaneously
positive forHBVDNA,HCVRNAandHIVRNA. LowerCD4+cell count
was a risk factor for active HBV or HCV infection. HBV DNA posi-
tivity was 44.1% (15/34) and 20.6% (7/34) for CD4+ cell count <350
cells/ml and > 350 cells/ml, respectively. Similarly, HCV RNA posi-
tivity was 23.5% (8/34) and 14.7% (5/34) for CD4+ cell count <350
cells/ml and > 350 cells/ml, respectively. Surprisingly, ALT and AST
levels were normal for all but 2 patients. Most of the patients with
a detectable HIV viral load and/or CD4+ cell count <350 cells/ml at
baseline were initiated on HAART before cancer therapy.
Conclusion: To our knowledge, this is the ﬁrst study to report
relatively high simultaneous detection of HBV, HCV and HIV active
infection in cancer patients in this region. The study advocates for
intensiﬁed screening of HBV and HCV in cancer patients before
initiation of HAART and/or cancer therapy, and where indicated,
anti-viral treatment should be extended to HBV and/or HCV, to
minimize the risk of liver disease.
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